Background: The introduction of the new simultaneous PET/MRI scanner opens new opportunities in functional imaging.
Introduction
The ability to fuse images from two or more modalities is always interesting, but to acquire them simultaneously or within a narrow window of a few seconds or minutes is exciting as it opens the potential of utilizing the various functional parameters into a single study.
Positron emission tomography (PET) is able to image multiple functional parameters depending on the radiotracer used. The most common clinically available tracer, familiar to most physicians, is Fluorine-18 fluorodeoxyglucose ( 18 F-FDG), which reflects the glucose metabolism in normal and abnormal tissues, including tumours. PET is able to indicate the degree of metabolic activity by providing a semi-quantitative measure of glucose metabolism. Other less common tracers include fluorine-18 choline ( 18 F-choline), fluorine-18 fluorothymidine ( 18 F-FLT) and Fluorine-18-fluoride (Table 1) . Each of these tracers reflects a different parameter, which can be imaged in normal and disease states. The ability to successfully co-register these functional images with CT and thereby create PET/CT was first achieved in 1998. The use of PET/CT has steadily increased since then, initially for imaging of lung disease and lymphoma and later across a broad range of pathologies. Furthermore, more diseasespecific tracers have been increasingly used, including 18 F-choline for the evaluation of brain tumours and prostate cancer, 68 Ga-DOTATATE for neuroendocrine tumours and 18 F-DOPA for insulinomas. 1 PET/CT now has many approved indications and is included in guidelines for tumour staging and response assessment in the UK (http://www.rcplondon.ac.uk/ resources/evidence-based-indications-use-pet-ct-uk-2012).
Magnetic resonance imaging (MRI) is able to provide excellent soft tissue resolution and therefore anatomic detail and has the benefit of not using ionizing radiation. In recent years, there has been an ongoing trend towards expansion of the functional components of MRI and identification of their clinical utility. As a consequence, MRI can now serve as a combined anatomical and functional imaging modality and is constantly evolving, with the modification of existing and the development of new sequences. Many studies over the past decade have combined data from independent PET and MRI studies, showing the potential utility of quantitative biomarkers from each modality. However, these investigations were not performed on simultaneous PET/MRI scanners and therefore had major limitations in respect of the interval between studies and the potential for misregistration of vital structures. [2] [3] [4] [5] Although the concept of combining PET and MRI into a single scanner has been discussed for more than two decades, there have been several major obstacles to the development of a viable scanner. The main hurdles have included (a) photomultiplier tube technology, requiring replacement with magnetic field-insensitive photodiodes; (b) the need to create PET detectors in a format which would not interfere with MRI field gradients or radiofrequency and (c) the absence of a suitable way to perform attenuation correction. Advances in technology have overcome most of these hurdles, with the development of MRI-compatible photodiodes (avalanche photodiodes) and the use of a two-point Dixon technique (a method of fat suppression) for attenuation correction. 6 These advances resulted in the introduction in 2010 of the first generation of whole-body PET/MRI scanners. This review looks at the potential of this new technology and shares our experience of using PET/MRI (Siemens mMR) in clinical practice. The focus is on potential clinical applications in a setting without direct access to a cyclotron.
Sources of data
A PubMed/Medline search across all English language articles was performed using the keyword PET/MRI. The search was limited to 1 January 2011-31 March 2013. Only those studies and articles where PET/MRI was performed on a single scanning system were evaluated further, i.e. those studies which performed the investigations independently and/or used fusion techniques were not included in the review. Articles with a focus on potential human applications were selected. Fifty-nine articles were identified. Of these, 22 were of a review format, without original data and 19 addressed technical or physics-based issues such as attenuation correction or artefacts. Three articles evaluated a broad range of pathologies in a cross-over comparison format (PET/MRI versus PET/CT), five specifically assessed oncology applications and five focussed on neurological or head and neck applications. Of the remaining articles, one was on a cardiovascular topic, one was an oncology-related case report and three evaluated potential molecular pharmacological advances in relation to PET/MRI.
Areas of agreement
MRI has better soft tissue contrast than CT, warranting the use of PET/ MRI rather than PET/CT when this characteristic is important. Prospective areas of application include, in particular, oncology, cardiac imaging and neurology.
Oncology
Tumour phenotyping is a key potential role of PET/MRI, given the range of quantitative biomarkers which are evaluable in a single investigation. The ability to use these parameters to distinguish less from more aggressive tumours could have profound effects on risk stratification, prognostication and management strategies.
PET/MRI will be of particular benefit for imaging tumour sites, which have traditionally been better evaluated with MRI than with CT. These include the head and neck, heart, liver, female pelvis, prostate and rectum and PET imaging in tumours of these sites is known to be of potential use. [7] [8] [9] [10] MRI plays an important role in staging of these tumours. It has been postulated that combining information from PET, anatomical detail from high-resolution, small field of view T2-weighted imaging and functional MRI sequences, including diffusion, will further improve the accuracy in T staging. In our experience this potential benefit has been realized in only a limited number of patients (J. Bomanji, personal communication). Similarly, nodal disease may benefit from combined functional assessment, given the well-known limitations of size-specific cut-off in distinguishing benign from malignant lymph nodes. However, to date, only similar N staging accuracy has been found when PET/MRI is applied as a whole-body staging approach, compared with PET/CT. 11 Although no large-scale prospective data are available at present, in our experience there is a potential for PET/MRI to further refine TNM staging in limited numbers of cases of cervical cancer, prostate cancer, recurrent breast cancer, lymphoma (Fig. 1) , myeloma (solitary lesions) and head and neck cancers (Fig. 2) . In a multi-reader study of 50 patients at out institution, there was a 10% improvement in local staging using PET/MRI compared with PET/CT and confidence in anatomical localization of lesions improved by 5.1%. 12 Monitoring of treatment response in these tumours will also benefit from PET/MRI (Fig. 3) .
Imaging of brain tumours is a major potential use of PET/MRI, with the same goals as apply to the imaging of other tumours. Specific tracers such as 18 F-FLT, 18 F-choline (Fig. 4) and 68 Ga-DOTATATE (for meningiomas, Fig. 5 ), when used for PET/MRI, may enable the target volume to be altered in radiotherapy planning; this might have a significant effect on patient outcome and be of key importance when radiotherapy or surgery is being planned in areas of the brain with critical function. 
Cardiac imaging
The expectation remains that the PET/MRI scanner will exploit the superior tissue contrast inherent in the MRI component of the machine and the multi-parametric functional information provided by PET in cardiac disease states.
14 Currently, the role of PET/MRI in evaluating suspected or known coronary artery disease is limited in view of the established relatively cheap competing modalities such as stress echo, CT calcium score/CT angiography and myocardial perfusion scintigraphy. The potential value of PET/MRI in non-ischaemic cardiomyopathies remains to be tested and the availability of specific tracers such as 18 F-flutemetamol for amyloidosis and 18 F-FDG for cardiac sarcoidosis remains to be exploited (Fig. 6 ). Plaque characterization is another potential indication for combined PET/MRI, where, using the PET tracer 18 F-integrin (α v β 3 ) and MRI parameters of water content, chemical composition, physical state and molecular motion within plaque could be characterized.
On a research level there may be a role for PET/MRI in the assessment of cellular and gene therapies, such as in cardiac stem cell transplantation. In vivo tracking of therapies by non-invasive imaging would be of great benefit. 15 It has been proposed that by using information from PET/MRI performed using a macrophage-targeted nanoparticle labelled with 64 Cu, a key wound healing process (removal of necrotic tissue) may be identified after infarction, and that this process may be an important prognostic factor. 16 Dual labelled PET/MRI probes are an exciting area of ongoing research in cardiovascular disease. For targeting vascular inflammation and integrin α v β 3 expression, the use of magnetic nanoparticles coupled to chelated 64 Cu has been studied. 17, 18 Fig. 4 (a and b) T2 axial (a) and 18 F-choline PET/MRI axial image (b). A right thalamic glioblastoma multiforme had been surgically removed. Haemorrhagic change is seen in the surgical cavity, with some peripheral nodular tissue. These nodular areas are seen to demonstrate 18 F-choline uptake on PET/MRI, indicating residual disease (white arrows).
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In neurodegenerative diseases and dementia, motion and partial volume effects can limit the accuracy of PET, e.g. in the presence of regional atrophy, cortical hypometabolism may be overestimated using 18 F-FDG. 19 MRI-based motion and partial volume effect correction can be utilized to optimize imaging as well as to obtain functional MRI parameters.
MRI scanning can also be used to derive information about brain activity, and there is increasing interest in the use of functional MRI as a diagnostic tool in dementia. Individually, both 18 F-FDG PET/CT and structural MRI are able to distinguish patients with Alzheimer's disease (AD) from control subjects with a diagnostic accuracy in excess of 90%, but they are less accurate in differentiating AD from other degenerative dementias. 19 A combination of PET and MRI is likely to result in increased accuracy in differential diagnosis, especially during early phase of disease or with subtle changes on either modality, which is currently hampered by sequential scanning of patients on separate scanners and the attendant logistical difficulties and impact on correlative analysis of scan data.
The ability to undertake simultaneous PET/MRI scanning on an integrated system not only overcomes these difficulties but also represents a significant improvement over currently available PET/CT systems with regard to anatomical co-registration of the PET imaging data. The commercial availability of 18 F-flutemetamol for amyloid plaque burden delineation in early dementia holds significant promise and will exploit the strength of PET/MRI. In addition to the potential diagnostic benefits, simultaneous multimodal imaging may help to identify other more sensitive and specific biomarkers (e.g. τ protein) for early dementia that could be used in interventional trials aimed at delaying progression of dementia. 20 It is felt that 18 F-FDG PET/MRI will be useful in patients with epilepsy where blood flow, metabolism and spectroscopy will help in localizing/ lateralizing the epileptogenic focus, which would be helpful in management, and particularly surgical planning, using the co-registered images.
In stroke imaging, the ischaemic penumbra as identified by PET provides valuable information on salvageable brain tissue. 21 Nevertheless, since the tracers which are used to generate this information are not widely available, particularly in an emergency setting, CT and, increasingly, MRI are used instead. However, perfusion and diffusion-weighted imaging on MRI does not correlate precisely with the PET penumbra. 22 Simultaneous PET/MRI acquisition may lead to optimization of treatment planning in patients with ischaemic stroke in the acute setting and also permit monitoring of lesion progression. The potential to obtain simultaneous quantitative data from PET and functional MRI may make possible the acquisition of information on neurotransmitter-mediated processes such as in Parkinson's disease, where receptor expression and neuronal activation may be monitored as part of pharmacological response assessment by PET and MRI, respectively. 22 
Areas of controversy
The main controversy regarding PET/MR is its specific clinical role and cost-effectiveness.
Financial considerations
Few doubt the potential benefit of using multiple quantitative imaging biomarkers with PET/MRI. However, the financial burden of running a combined PET/MRI scanner is considerable. In addition, efficient running requires dual-trained nuclear medicine physicians, radiologists, technologists, radiographers and physicists who are difficult to find and recruit, a difficulty compounded by lack of formal PET/MRI training programmes.
Service challenges
As with all new technologies, there are other competing modalities. In the context of PET/MRI there is a trend towards the fusion of PET/CT and MRI images acquired on separate machines within a short time interval. This is made possible by recent advances in image registration and motion correction, which improve the data quality obtained with nonsimultaneous PET/CT and MRI. It is therefore arguable if investment in a simultaneous PET/MRI machine is justifiable.
Although this review focussed on potential clinical applications of PET/ MRI, there are undoubtedly major potential research applications of this imaging modality. As acquisition of the scanner may depend on joint clinical and research funds, a potential service challenge is to accommodate both clinical and research studies throughout the scanning day. This may be particularly challenging as complex clinical cases, which are evaluated may be under time pressure of impending deadlines for surgery and research studies may contain multiple experimental sequences, adding to overall scanning time.
Utilization of tracers such as oxygen-15, carbon 11 and other shortlived radiotracers is not possible without direct access to a cyclotron. It is, however, possible to combine some useful tracers with fluorine, which increases half life, for example fluorocholine as an alternative to carbon choline.
Growing points
Many patients undergo PET/CT imaging and MRI during the course of their management, often within a short time interval. In such cases, the opportunity to perform a combined scan will be beneficial to the patient pathway by reducing the number of patient visits. Reduction of the ionizing radiation dose with PET/MRI is another advantage. The radiation exposure from the hybrid PET/MR imaging has been reportedly 80% less than a PET/CT study. 23 This is particularly important when considering serial scans in response assessment and when imaging those most vulnerable to the effects of radiation-the paediatric population.
As work with novel tracers continues, it is important to validate imaging-based phenotyping from both PET and MRI with gold standards such as pathological correlates. For example, hypoxia in tumours may be evaluated using FMISO and Blood Oxygen Level-Dependent MR imaging during simultaneous PET/MRI, but this must be evaluated against hypoxia quantified from histopathology. Similarly, angiogenesis tracers such as rubidium and dynamic contrast-enhanced MRI performed simultaneously can be evaluated against histopathological quantification of angiogenesis. This research may yield important information to guide which are the optimum and most accurate phenotyping sequences for future protocols.
There are also growing points in terms of technology within PET/MRI to improve image acquisition. Attenuation correction algorithms using MR data are being continually being developed, particularly in brain imaging. MR-based motion correction technologies to correct for gross patient motion and breathing are also under development and are particularly important given relatively long PET data acquisition times.
The optimal clinical applications of PET/MRI remain to be established. Finding the 'key application' will secure the role of PET/MRI in patient management. Currently, a large-scale indication remains elusive and until research can prove clinical benefit, against important outcome measures, the technology will remain in its infancy.
Conclusion
PET/MRI is one of the most exciting developments in imaging in recent years. There is scope within oncology, neurology and cardiac imaging for this modality to develop, although widely accepted clinical indications remain to be defined. The growing use of novel tracers and functional MRI parameters offers great potential benefit; this is especially evident in research but there are also various clinical applications in which optimal molecular information might be acquired, guiding the management of patients. Ultimately, many factors will decide the clinical role of PET/ MRI in the NHS. The cost of the system and the clinical benefit to the patient compared with PET/CT will be the main driving forces in this context.
